Xencor Inc. Common Stock is a pharmaceutical company that focuses on developing innovative antibody therapeutics to treat severe autoimmune diseases and cancer. Its proprietary XmAb® technology platform enables the creation of highly specific and potent antibodies. The company has a robust pipeline of novel drug candidates and strategic partnerships with leading biopharmaceutical companies. Xencor strives to revolutionize patient care through cutting-edge science and transformative therapies.
